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ABSTRACT We sought to define trends in and predictors of carbapenem con-
sumption across community, teaching, and university-affiliated hospitals in the
United States and Canada. We conducted a retrospective multicenter survey of
carbapenem and broad-spectrum noncarbapenem beta-lactam consumption be-
tween January 2011 and December 2013. Consumption was tabulated as defined
daily doses (DDD) or as days of therapy (DOT) per 1,000 patient days (PD). Multi-
variate mixed-effects models were explored, and final model goodness of fit was
assessed by regressions of observed versus predicted values and residual distri-
butions. A total of 20 acute-care hospitals responded. The centers treated adult
patients (n  19/20) and pediatric/neonatal patients (n  17/20). The majority of
the centers were nonprofit (n  17/20) and not affiliated with medical/teaching
institutions (n  11/20). The median (interquartile range [IQR]) carbapenem con-
sumption rates were 38.8 (17.4 to 95.7) DDD/1,000 PD and 29.7 (19.2 to 40.1)
DOT/1,000 PD overall. Carbapenem consumption was well described by a multi-
variate linear mixed-effects model (fixed effects, R2  0.792; fixed plus random
effects, R2  0.974). Carbapenem consumption increased by 1.91-fold/quarter
from 48.6 DDD/1,000 PD (P  0.004) and by 0.056-fold/quarter from 45.7 DOT/
1,000 PD (P  0.93) over the study period. Noncarbapenem consumption was in-
dependently related to increasing carbapenem consumption (beta  0.31 for in-
creasing noncarbapenem beta-lactam consumption; P  0.001). Regular antibiogram
publication and promotion of conversion from intravenous (i.v.) to oral (p.o.) ad-
ministration independently affected carbapenem consumption rates. In the final
model, 58.5% of the observed variance in consumption was attributable to
between-hospital differences. Rates of carbapenem consumption across 20 North
American hospitals differed greatly, and the observed differences were correlated
with hospital-specific demographics. Additional studies focusing on the drivers of
hospital-specific carbapenem consumption are needed to determine whether
these rates are justifiable.
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Resistance to last-line antimicrobials, including carbapenems (C), among Gram-negative bacteria has been labeled as an urgent public health threat (1). Economic
modeling suggests that the current U.S. rates of infections caused by carbapenem-
resistant Enterobacteriaceae produce excess hospital and third-party payer costs of over
$422 million combined, in addition to costing society over $553 million as a whole (2).
Decreases in carbapenem effectiveness have been driven by increasing resistance and
higher MICs (3–5). Carbapenem resistance is associated with higher morbidity, reduc-
tions in initial active antibiotic treatment, and worse patient outcomes (6–10). Recent
studies found that Gram-negative bloodstream infections caused by carbapenem-
resistant bacteria are associated with crude mortality rates of between 20% and 50%
(11–15). As a result, to address the current crisis of carbapenem resistance, antibiotic
stewardship programs have focused on limiting carbapenem use to cases in which
more-narrow therapy is not feasible.
Antibiotic stewardship programs are ideally positioned to address carbapenem
resistance by developing and implementing interventions to improve carbapenem use
and by monitoring carbapenem consumption. Previous investigations have demon-
strated that higher rates of carbapenem consumption correlate with higher rates of
carbapenem resistance (16–18). Limiting unnecessary carbapenem use has been shown
to produce favorable effects on the resistance rates of problematic nosocomial patho-
gens such as Pseudomonas aeruginosa (19). Importantly, antibiotic consumption is one
of the few drivers of antimicrobial resistance that antibiotic stewards can influence.
Therefore, measuring consumption is a critical component of successful antibiotic
stewardship efforts.
Determination of how the rate of carbapenem consumption in a given hospital
correlates to rates in other hospitals is a necessary first step in benchmarking use.
Improved understanding of the drivers of carbapenem use is important because
carbapenems represent the fourth most commonly used antibiotic class in within
hospitals (20) and because unnecessary carbapenem use increases the risk of acquiring
carbapenem-resistant pathogens (21). Therefore, we conducted a cross-sectional survey
to understand potential drivers and contemporaneous rates of carbapenem consump-
tion across small and large hospitals from the Making a Difference in Infectious Diseases
(MAD-ID) network. The ability to compare the carbapenem consumption rate of a given
hospital to that of similar institutions is an essential element in determining whether
local consumption is above or below the level in benchmark hospitals; however, this
task complicated by between-institution differences (e.g., hospital size, number of
intensive care unit [ICU] beds, etc.) and the choice of consumption metrics (22, 23).
Here, we sought to evaluate trends in and predictors of carbapenem consumption
across 20 demographically and geographically diverse North American hospitals.
(These findings were presented, in part, as a poster at the American Society of
Health-System Pharmacists Midyear Clinical Meeting in December 2014, at the Making
a Difference in Infectious Diseases [MAD-ID] Annual Meeting in May 2015, and as a
platform presentation at the Interscience Conference of Antimicrobial Agents and
Chemotherapy [ICAAC/ICC] Meeting in September 2015.)
RESULTS
Demographics of participating centers. Among the 181 network sites, 20 partic-
ipating centers contributed antimicrobial consumption and demographic data. A total
of 9 centers reported consumption in defined daily doses (DDDs), and 11 reported
consumption in days of therapy (DOTs). Over 12 quarters spanning January 2011 to
December 2013, participating centers provided a total of 228 consumption observa-
tions from 240 possible observations. Consumption data were not reported from
quarters 1 and 2 by 3 centers, quarters 3 and 4 by 2 centers, or quarters 5 and 6 by 1
center. Data corresponding to administrations were available from 6 centers, while the
remaining 14 centers relied on dispensing records. The demographics of the partici-
pating centers are shown in Table 1 and stratified according to DDD or DOT reporting
status. The majority of participating centers (n  17/20) were not-for-profit institutions.
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Among the not-for-profit institutions, 59% reported DOTs (n  10/17) and 41% re-
ported DDDs. Most centers served both adults (95%) and pediatric (70%) populations.
A minority of centers served neonatal patients (15%) or a long-term-care population
(10%). Numbers of beds ranged from between 100 and 249 to 750 among the
participating centers. Numbers of beds were fairly evenly distributed across DDD-
reporting hospitals (Table 1). DOT-reporting hospitals commonly had between 250 and
499 beds (45.5%, n  5/11), which was also the most common number of beds overall
(35%, n  7/20). DOT-reporting hospitals were numerically more likely to have between
30 and 59 ICU beds compared to DDD-reporting hospitals (36.4 versus 0%; P  0.09).
Overall, facilities within the response sample represented a collection of demograph-
ically diverse hospitals from our network.
Antimicrobial stewardship characteristics. Participating centers employed a va-
riety of self-reported antimicrobial stewardship strategies to control carbapenem use at
each site, as shown in Table 1. The most common self-described antimicrobial stew-
ardship strategy employed was annual antibiogram dissemination (95%, n  19/20).
Most participating centers utilized combination approaches that included the follow-
ing: antimicrobial prescribing guidelines (85%), prospective audit and feedback for
prescribers (80%), active policies promoting conversion from intravenous (i.v.) to oral
(p.o.) administration (75%), and antimicrobial formulary restrictions (70%). Only a
minority of participating centers reported using rapid diagnostic testing for early
identification of pathogens at the time of the survey (20%). Likewise, only 40% of








Hospital classification, n (%)
University 3 (33.3) 6 (54.6) 0.41
Nonprofit 7 (77.8) 10 (90.9) 0.57
For-profit 1 (11.1) 0 (0) 0.45
Governmental 1 (11.1) 2 (18.2) 0.99
Population served, n (%)
Adult 9 (100) 10 (90.9) 0.99
Pediatric 7 (77.8) 10 (90.9) 0.57
Neonatal 1 (11.1) 2 (18.2) 0.99
Long-term care 1 (11.1) 1 (9.1) 0.99
No. of licensed beds, n (%)
100–249 2 (22.2) 0 (0) 0.19
250–499 2 (22.2) 5 (45.5) 0.37
500–749 2 (22.2) 4 (36.4) 0.64
More than 750 3 (33.3) 2 (18.2) 0.62
No. of ICU beds, n (%)
0–9 1 (11.1) 0 (0) 0.45
10–29 4 (44.4) 1 (9.1) 0.13
30–59 0 (0) 4 (36.4) 0.09
More than 60 4 (44.4) 6 (54.6) 0.99
Stewardship strategy, n (%)
Formulary 5 (55.6) 9 (81.8) 0.34
Prospective audit and feedback 7 (77.8) 9 (81.8) 0.99
Electronic decision support 3 (33.3) 8 (72.7) 0.18
i.v. to p.o. conversion 7 (77.8) 8 (72.7) 0.99
Utilization guidelines 8 (88.9) 9 (81.8) 0.99
Order forms 6 (66.7) 2 (18.2) 0.07
Rapid diagnostics 1 (11.1) 3 (27.3) 0.59
Antibiogram dissemination 8 (88.9) 11 (100) 0.45
aDemographic data are stratified by the institution’s ability to report consumption in defined daily doses
(DDDs) or days of therapy (DOTs).
bComparisons were performed using the chi-square test or Fisher’s exact test.
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centers reported using specialized medication order forms to control carbapenem use.
There were no significant differences in the types of self-reported antimicrobial stew-
ardship strategies used to control carbapenem use between DDD-reporting and DOT-
reporting centers (Table 1). However, numerically more DDD-reporting centers than
DOT-reporting centers utilized carbapenem order forms (66.7% [n  6/9] versus 18.2%
[n  2/11], respectively; P  0.07).
Variability in antimicrobial consumption across demographics. The rates of
consumption of carbapenems (i.e., doripenem, ertapenem, imipenem-cilastatin, and
meropenem) and noncarbapenem (NC) beta-lactam (i.e., cefepime and piperacillin-
tazobactam) in DDD/1,000 patient days (PD) are shown in Table 2. Meropenem was the
most commonly utilized carbapenem (44% of carbapenem DDDs) followed by ertap-
enem (40.3% of DDDs), while imipenem-cilastatin and doripenem were infrequently
utilized (8.9 and 6.8% of DDDs, respectively). Carbapenem DDDs were highly variable.






University (n  3) 17.3 (12.4–106) 51.4 (5.1–67.1) 3
Not-for-profit (n  7) 25.5 (15.5–46.7) 73.2 (6.5–208) 2.9
For profit (n  1) 60.2 (41.9–65.1) 214 (174–280) 3.6
Governmental (n  1) 11.3 (10.4–15.7) 1.0 (0.8–5.1) 0.1
Population served
Adult (n  9) 38.8 (17.4 –95.7) 77.7 (42.2–210) 2
Pediatric (n  7) 39.8 (17.9–109) 74.1 (6.6–229) 1.9
Neonatal (n  1) 15.2 (13.1–18.3) 63.3 (58.6–85.5) 4.2
Long-term care (n  1) 11.3 (10.4–15.7) 1.0 (0.8–5.1) 0.1
No. of licensed beds
100–249 (n  2) 104 (60.2–119) 112 (51.4–214) 1.1
250–499 (n  2) 18.3 (11.3–26.3) 3.6 (1.0–5.0) 0.2
500–749 (n  2) 21.5 (15.0–74.9) 58.6 (49.8–65.5) 2.7
750 or more (n  3) 43.2 (20.8–171) 217 (101–380) 5
No. of ICU beds
0–9 (n  1) 118.7 (106.2–125) 51.4 (47.2–69.1) 0.4
10–29 (n  4) 34.4 (16.8–62.2) 8.9 (3.5–150) 0.3
30–59 (n  0)
60 or more (n  4) 31.5 (15.9–100) 151.6 (88.3–317) 4.8
Stewardship strategy
Formulary (n  5) 76.5 (39.2–125) 96.2 (53.2–232) 1.3
Prospective audit and feedback (n  7) 38.8 (18.1–67.5) 59 (6.5–178) 1.5
Electronic decision support (n  3) 40.3 (19.5–46.7) 96.2 (58.8–208) 2.4
i.v. to p.o. conversion (n  7) 46.7 (18.5–111) 96.2 (49.7–230) 2.1
Utilization guidelines (n  8) 43.8 (19.8–106) 86.6 (10.5–218) 2
Order forms (n  6) 43.8 (23.4–78) 50.2 (4.4–200) 1.1
Rapid diagnostics (n  1) 76.5 (55.1–86.9) 49.7 (48–54.5) 0.7
Antibiogram dissemination (n  8) 43.8 (19.8–106) 86.6 (10.5–218) 2
Class-specific consumption rates
All carbapenems 38.8 (17.4–95.7) 77.7 (42.2–210) 2
Agent-specific consumption rate (mean  SD)
Cefepime 67.5  88.9
Piperacillin-tazobactam 58.6  66.2
Ertapenem 26.6  27.1
Doripenem 11.6  35.5
Imipenem-cilastatin 1.5  3.4
Meropenem 20.9  25.2
aData represent defined daily doses (DDDs) per 1,000 patient days (PD) observed over 12 quarters.
bRates are presented as median (IQR) unless otherwise specified.
cNC/C, noncarbapenem-to-carbapenem median consumption ratio.
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Among the centers reporting DDDs, the overall median (interquartile range [IQR])
consumption rate of carbapenems across the entire 3-year study period was 38.8 (17.4
to 95.7) DDD/1,000 PD. The corresponding 3-year noncarbapenem beta-lactam con-
sumption rate was 77.7 (42.2–210.1) DDD/1,000 PD. The percent coefficients of varia-
tion (i.e., standard deviation [SD]/mean  100) for carbapenem and noncarbapenem
consumption were 94.3 and 100.3%, respectively. Across all hospital demographics, the
highest levels of carbapenem consumption were noted at smaller facilities (median
[IQR], 104 [60.2 to 119]; n  2) and facilities with 9 or fewer ICU beds (median [IQR],
118.7 [106.2 to 125]; n  1), while the lowest levels of consumption were observed at
governmental facilities and facilities that provide long-term care (median [IQR], 11.3
[10.4 to 15.7]; n  1).
Rates of consumption of carbapenem and noncarbapenem beta-lactams are also
compared according to DDD reporting status in Table 2. Noncarbapenem consumption
was generally 1.1-fold to 5-fold greater than carbapenem consumption in DDD/1,000
PD across demographic categories. Exceptions to this trend were observed at facilities
that provide long-term (noncarbapenem-to-carbapenem median consumption [NC/C]
ratio, 0.1; n  1), at governmental facilities (NC/C ratio, 0.1; n  1), at medium-sized (i.e.,
250 to 499 licensed beds) facilities (NC/C ratio, 0.2; n  2), at centers with 29 or fewer
ICU beds (NC/C ratio, 0.3 to 0.4; n  5), and at facilities that utilized rapid diagnostics in
their antimicrobial stewardship efforts (NC/C ratio, 0.7; n  3). Notably, smaller facilities
(i.e., 100 to 249 licensed beds; n  2) and centers that utilized order forms to limit
carbapenem use (n  2) exhibited carbapenem consumption rates in DDDs that were
similar to the noncarbapenem consumption rates (NC/C ratio, 1.1; n  2).
The rates of carbapenem and noncarbapenem beta-lactam consumption in DOT/
1,000 PD are shown in Table 3. Meropenem was the most commonly utilized carbap-
enem (49% of carbapenem DOTs), while imipenem-cilastatin, doripenem, and ertap-
enem were all utilized less frequently (20.1, 15.6, and 15.3% of DOTs, respectively).
Carbapenem consumption rates in DOT/1,000 PD were also highly variable, similarly to
the levels of variability observed in the centers reporting consumption in DDD/1,000
PD. Among the centers reporting DOTs, the overall median (IQR) consumption rate of
carbapenems during the 3-year study period was 29.7 (19.2 to 40.1) DOT/1,000 PD. The
corresponding 3-year median (IQR) consumption rate of noncarbapenem beta-lactams
was 102 (69.4 to 131) DOT/1,000 PD. The percent coefficients of variation for carbap-
enem and noncarbapenem beta-lactam consumption were 90.1 and 123%, respec-
tively. Across all hospital demographics, the highest levels of carbapenem consumption
in DOTs were noted within the centers that used order forms to restrict carbapenem
use (median [IQR], 180 [12.4 to 216]; n  2) as well as in the governmental facilities
(median [IQR], 38.2 [29.1 to 48.3]; n  2) and in the facilities that provide long-term care
(median [IQR], 35.5 [34.1 to 39.9]; n  1), while the lowest levels of consumption were
observed at the university teaching hospitals and the centers with 60 or more ICU beds
(median [IQR], 21.8 [16.9 to 35.4]; n  6).
Rates of consumption of carbapenems and noncarbapenem beta-lactams are com-
pared according to DOT reporting status in Table 3. In contrast to DDD-reporting
centers, DOT-reporting centers experienced noncarbapenem consumption rates that
were consistently higher than the rates of carbapenem consumption. Consumption of
noncarbapenem beta-lactams in DOT/1,000 PD was 1.7-fold to 6.1-fold greater than
carbapenem consumption across all evaluated demographics (Table 3).
Variability in antimicrobial consumption across institutions. The relationship
between carbapenem consumption and noncarbapenem beta-lactam consumption is
displayed in Fig. 1. Carbapenem consumption appeared to be moderately to highly
positively correlated with noncarbapenem beta-lactam consumption for both DDD-
reporting and DOT-reporting centers in the univariate analysis (r  0.65 and 0.94,
respectively; P  0.001 for each). However, the carbapenem consumption rates were
not uniform across centers. The influence of high-consumption centers was assessed
among DDD-reporting centers. Two DDD-reporting centers demonstrated carbapenem
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consumption rates that were, on average, 4.5-fold higher than those of all other
DDD-reporting centers combined. The overall correlation between carbapenem and
noncarbapenem beta-lactam consumption appeared to be influenced by the data from
these two centers. When the data from these centers were removed, the correlation
coefficient reflecting carbapenem and noncarbapenem consumption in DDD/1,000 PD
fell from 0.65 to 0.43 (P  0.001) with a corresponding decrease in the R2 value from
0.427 to 0.187 (Fig. 1A and C). Likewise, among the DOT-reporting centers, a single
center demonstrated carbapenem consumption rates that were, on average, 7.2-fold
higher than those of all the other centers combined. The overall correlation between
carbapenem and noncarbapenem beta-lactam consumption appeared to be heavily
influenced by the data from a single center. When the data from this center were
removed, the correlation coefficient reflecting carbapenem and noncarbapenem beta-
lactam consumption in DOT/1,000 PD fell from 0.94 to 0.11 (P  0.25) with a corre-
sponding decrease in the R2 value from 0.877 to 0.012 (Fig. 1B and D).






University (n  6) 21.8 (16.9–35.4) 110 (75.6–128) 5
Nonprofit (n  10) 30.9 (21.0–41.9) 107 (68.0–134) 3.5
For-profit (n  0)
Governmental (n  2) 38.2 (29.1–48.3) 113 (91.1–128) 3
Population served
Adult (n  10) 30.9 (21.4–42.0) 110 (76.7–136) 3.6
Pediatric (n  10) 30.9 (20.9–42.0) 93.6 (67.9–128) 3
Neonatal (n  2) 18.7 (12.4–21.8) 113.9 (76.7–125.2) 6.1
Long-term care (n  1) 35.5 (34.1–39.9) 59.8 (58.1–72.7) 1.7
No. of licensed beds
100–249 (n  0)
250–499 (n  5) 34.2 (20.2–42.1) 68.9 (54.1–107) 2
500–749 (n  4) 23.9 (19.4–43.2) 130 (123–147) 5.4
750 or more (n  2) 23.8 (12.4–30.0) 84.0 (76.7–92.8) 3.5
No. of ICU beds
0–9 (n  0)
10–29 (n  1) 35.5 (34.1–39.9) 59.8 (58.1–72.7) 1.7
30–59 (n  4) 31.9 (24.5–93.5) 111.6 (78.5–285) 3.5
60 or more (n  6) 21.8 (16.9–35.4) 110 (75.6–128) 5
Stewardship strategy
Formulary (n  9) 23.9 (18.3–34.4) 102 (73.3–138) 4.2
Prospective audit and feedback (n  9) 30.8 (20.7–42) 103 (67–130) 3.3
Electronic decision support (n  8) 29.1 (19.5–36.9) 96.4 (73–131) 3.3
i.v. to p.o. conversion (n  8) 25.9 (19.2–34.1) 93.6 (72.6–123) 3.6
Utilization guidelines (n  9) 25.4 (18.5–36.2) 91.7 (64.5–128) 3.6
Order forms (n  2) 180 (12.4–216) 423 (76.7–491) 2.3
Rapid diagnostics (n  3) 31.4 (18.2–36.1) 58.9 (43.9–73.3) 1.9
Antibiogram dissemination (n  11) 29.7 (19.2–40.1) 102 (69.4–131) 3.4
Class-specific consumption rates
All carbapenems 29.7 (19.2–40.1) 102 (69.4–131) 3.4
Agent-specific consumption rate (mean  SD)
Cefepime 30.2  17.2
Piperacillin-tazobactam 105  108
Ertapenem 8.1  16.4
Doripenem 15.7  38.6
Imipenem-cilastatin 7.6  13.3
Meropenem 14.4  12.7
aData represent days of therapy (DOTs) per 1,000 patient days (PD) observed over 12 quarters.
cAll rates are presented as median (IQR) unless otherwise specified for specific agents.
cNC/C, noncarbapenem-to-carbapenem median consumption ratio.
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Univariate and multivariate models of antimicrobial consumption over time.
After observing that antimicrobial consumption rates varied by DDD or DOT reporting
status and by hospital demographic characteristics and at the individual hospital level,
we next sought to identify whether any time trends existed with respect to antimicro-
bial consumption. Time-dependent linear trends in carbapenem consumption were
observed at the DDD-reporting centers (see Fig. S1 in the supplemental material),
whereas DOT-reporting centers demonstrated relatively time-invariant rates of con-
sumption (Fig. S2). The univariate linear regression over time revealed that carbapenem
consumption in DDD/1,000 PD increased by a factor of 2.2 each quarter over the 3-year
study period from an average baseline of 46.1 DDD/1,000 PD (P  0.001 for linear
trend). In contrast, the univariate linear regression of carbapenem consumption in
DOT/1,000 PD over time revealed that consumption decreased each quarter by a factor
of 0.47 from an average baseline of 49.1 DOT/1,000 PD (P  0.26 for linear trend). On
the other hand, univariate linear regressions in DDD-reporting centers revealed that
noncarbapenem beta-lactam consumption increased by a factor of 0.63 each quarter
from an average baseline of 121 DDD/1,000 PD (P  0.39). Likewise, univariate linear
regressions in DOT-reporting centers revealed that noncarbapenem beta-lactam con-
sumption increased by a factor of 0.38 each quarter from an average baseline of 133
DOT/1,000 PD (P  0.22).
Because consumption rates were highly clustered within hospitals, mixed-effects
models were used to identify population-level predictors of consumption. Parameter
estimates and standard errors for the final multivariate linear mixed-effects model of
carbapenem consumption are shown in Table 4. A within-center relationship was
observed between the rate of change in carbapenem consumption over time and the
FIG 1 Correlations between carbapenem and noncarbapenem consumption across 20 North American hospitals. Data represent correlations
between carbapenem and noncarbapenem consumption with and without outlier removal. (A) Correlation of carbapenem and noncarbapenem
DDDs/1,000 PD across all centers and quarters. r  0.65; R2  0.427. (B) Correlation between carbapenem and noncarbapenem DOTs/1,000 PD
across all centers and quarters. r  0.94; R2  0.877. (C) Reanalysis of data presented in panel A with 24 observations from two outlier institutions
removed from analysis. r  0.43; R2  0.187. (D) Reanalysis of data presented in panel B with 12 observations from a single outlier institution
removed from analysis. r  0.11; R2  0.012.
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average baseline consumption rate: thus, these variables appeared nonindependent.
Carbapenem consumption in DDD or DOT/1,000 PD was best and most parsimoniously
represented by a model consisting of 11 fixed-effects parameters. The goodness of fit
of the final model, as judged by regressions of predictions from the fixed-effects model
(i.e., population-level predictions) and the fixed-effects-plus-random-effects model (i.e.,
individual hospital-level predictions) for the observed carbapenem consumption rates
(classified per 1 unit carbapenem consumed/1,000 PD in the combined model), is
graphically displayed in Fig. 2. The final fixed-effects model was parameterized with 5
independent predictors (5 df), 1 categorical predictor of ICU bed number (the reference
group corresponded to 0 to 9 beds) with three levels (3 df), and an interaction between
consumption metric reported (i.e., DDD or DOT reporting status) and time (3 df). The
final linear mixed-effects model was significantly more parsimonious and explanatory
than the next most explanatory model with 10 parameters (Akaike’s information
criterion [AIC]  1,795 versus 1798.1; P  0.02 by likelihood ratio testing). Overall, the
fixed-effects predictions fit the observed consumption data reasonably well (Fig. 2A)
(R2  0.792; bias  0.03 units carbapenem consumed/1,000 PD; imprecision  7 units
carbapenem consumed2/1,000 PD2). The final random-effects model accounted for the
dependency of the rate of change in carbapenem consumption (i.e., slope) on the
average baseline consumption rate (i.e., intercept) at the individual hospital level.
The covariance of within-hospital random effects was estimated using an unstructured
variance-covariance matrix. The time-dependent slope and intercept were highly cor-
related for each hospital (working correlation, r  1), indicating a positive association.
In combination, the fixed-effects-plus-random-effects predictions fit the observed con-
sumption data very well (Fig. 2B) (R2  0.974; bias  0.0031 units carbapenem
consumed/1,000 PD; imprecision  0.873 units carbapenem consumed2/1,000 PD2).
The final mixed-effects model accounted for between-hospital differences in consump-
tion rates. The interclass correlation coefficient for the final model was 0.585. That is,
TABLE 4 Final linear mixed-effects model parameter estimates of carbapenem
consumptiona
Fixed effects (output) Estimateb SE P value RSE (%)
Time (quarters)c 0.056 0.60 0.93
MetricDDDc 13.8 7.76 0.08
Time  MetricDDDc 1.85 0.89 0.037
10–29 vs 0–9 ICU beds 111 11.4 0.001
30–59 vs 0–9 ICU beds 90.7 13.5 0.001
60 vs 0–9 ICU beds 112 11.6 0.001
250–499 licensed beds 28.2 6.12 0.001
Noncarbapenem consumption 0.31 0.02 0.001
Antibiogram publication 29.0 12.7 0.022
i.v. to p.o. conversion 27.8 6.36 0.001
Interceptc 84.0 18.0 0.001
Random effects (Zu)
Time, SD 1.78 0.34 19.3
Intercept, SD 11.4 2.86 25
Covariance (Time, intercept) 20.3 —d —d
Correlation (Time, intercept) 1 0.0000294 0.03
Residual error, SD 9.62 0.48 4.94
aEstimate, fixed-effects or random-effects parameter estimates; SE, standard error; RSE, relative standard
error; Zu, matrix of random-effects matrix variances and covariance of time-dependent slope and intercept
for each individual center that contributed data; Output, DDD/1,000 PD or DOT/1,000 PD; Metric, coded as
1 or 0 according to DDD or DOT reporting status as indicated in footnotes b to d; Time, quarters increasing
from 1 to 12; Time  MetricDDD (or Time  MetricDOT), the interaction between Time and MetricDDD (or
between Time and MetricDOT) for each respective consumption metric (as indicated in footnotes b to d).
bFixed effects for DDD/1,000 PD had the estimates as listed for each covariate.
cFixed effects for DOT/1,000 PD had different estimates (P values) for the following covariates: Time
(quarters), 1.91 (P  0.004); MetricDOT, 13.8 (P  0.08); Time  MetricDOT, 1.85 (P  0.037); Intercept, 15.2
(P  0.001).
d—, covariance SE and RSE not estimated because covariance was estimated in matrix form. Estimates for
the unstructured variance-covariance matrix (see Table 5) of the random effects (Zu) are as follows:
variance(time), 3.17; covariance(time, intercept), 20.3; variance(intercept), 130.
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holding the covariates constant, 58.5% of the observed variance in carbapenem
consumption was due to hospital-level differences.
Once the final model was selected, the impact of model covariates could be
assessed. We observed a significant time-dependent trend in carbapenem consump-
tion across the study period, holding constant all other covariates and within-hospital
differences. On average, carbapenem consumption at the DDD-reporting centers in-
creased by an adjusted factor of 1.91 each quarter from a mean baseline of 48.6
DDD/1,000 PD (P  0.037). On the other hand, carbapenem consumption increased on
average by a factor of 0.056 each quarter from a mean baseline of 45.7 DOT/1,000 PD
(P  0.93). Irrespective of DDD or DOT reporting status, carbapenem consumption
increased, on average, by 0.31 for every 1-unit increase in noncarbapenem beta-lactam
consumption. Other covariates that independently influenced carbapenem consump-
tion rates included the following: medium-sized centers with 250 to 499 hospital beds
(the carbapenem consumption rate increased 28-fold), centers with increasing numbers
of ICU beds (the carbapenem consumption rate decreased 90.7-fold to 112-fold com-
pared to centers with 0 to 9 ICU beds for each categorical increase in numbers of ICU
beds), centers that self-identified an antimicrobial stewardship strategy of active i.v. to
p.o. interventions (the carbapenem consumption rate decreased 28-fold), and centers
that utilized antibiogram publication as a self-identified antimicrobial stewardship
strategy (the carbapenem consumption rate increased 29-fold). The overall average
model predictions did not substantially change in the sensitivity analyses, excluding
ertapenem, potential outlier sites, and antibiogram publication as a self-identified
antimicrobial stewardship (Fig. S3).
DISCUSSION
We assessed carbapenem and noncarbapenem beta-lactam consumption data from
a group of 20 North American MAD-ID Research Network hospitals in a multicenter,
FIG 2 Population-level and individual hospital-level observed and model-predicted carbapenem consumption rates. (A) Fixed-effects model,
predicted versus observed carbapenem consumption. (B) Fixed- plus random-effects model, predicted versus observed carbapenem
consumption.
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retrospective study. Our analysis was unique in that we utilized mixed-effects models
to identify predictors of consumption across demographically diverse centers. These
models were able to accurately predict carbapenem consumption in a sample of
hospitals that exhibited highly variable consumption. After adjusting for between-
hospital demographic differences and consumption of noncarbapenem beta-lactams,
we observed significant time trends in consumption. Carbapenem DDD/1,000 PD
increased by a factor of 1.91 each quarter (P  0.004) in DDD-reporting centers. On the
other hand, carbapenem DOT/1,000 PD increased modestly, though not significantly
(P  0.93), by roughly 5.6% each quarter. Our findings suggest that centers that utilize
DDDs or DOTs exhibited different consumption trajectories even after adjusting for
facility demographics.
We identified several independent predictors of carbapenem use. Consumption of
noncarbapenem beta-lactams was independently and positively correlated with car-
bapenem consumption across all participating centers. Carbapenem consumption
increased on average by 0.31 for every 1-unit increase in noncarbapenem beta-lactam
consumption in the adjusted analysis, irrespective of DDD or DOT reporting status. We
also found an influence of i.v. to p.o. programs on reducing carbapenem consumption
(by an average of 28-fold) and an influence of disseminating antibiogram data as a
self-reported stewardship strategy on increasing carbapenem consumption (by an
average of 29-fold). The latter was an unexpected finding and may have been related
to a variety of factors, including unmeasured confounders, the method of presentation
of the antibiogram, and other stewardship strategies. Additional studies are needed to
clarify optimal stewardship strategies for controlling carbapenem use.
Previous investigations have evaluated differences in DDD and DOT consumption.
Polk and colleagues found that DDD correlated poorly with DOT for an array of
antibiotics across 130 U.S. hospitals (24). This finding was echoed by findings reported
by Dalton and colleagues from a study performed in Canada (25). However, time trends
were not explicitly evaluated. More recently, Baggs and colleagues evaluated time
trends in DOT-based consumption across 383 U.S. hospitals as a function of facility
demographics and populations served, using a methodology similar to ours. While they
did not observe time trends in overall consumption, they noted mean increases in
DOTs/1,000 PD for carbapenems, carbapenem alternatives (3rd and 4th generation
cephalosporins and beta-lactam/beta-lactamase inhibitor combinations), and glyco-
peptides (26). In our study, we also observed higher rates of carbapenem consumption
associated with facility characteristics. Facilities that were for-profit institutions (n  1)
or smaller institutions (i.e., 100 to 249 licensed beds) (n  2) exhibited higher DDDs/
1,000 PD. Likewise, we found higher rates of consumption in facilities that were
government-associated institutions (n  2), institutions that provided long-term care
(n  1), or medium-sized institutions (i.e., 250 to 499 licensed beds) (n  5) among
DOT-reporting centers. These findings underscore the need for population-adjusted
consumption benchmarks, which may ultimately be addressed through nationwide
benchmarking tools, such as the CDC National Healthcare Safety Network (NHSN)
standardized antimicrobial administration ratio (SAAR) (27).
Our report has implications for benchmarking efforts. Notably, our methodology
allowed us to account for within-hospital correlations between the rate of change in
carbapenem consumption and the baseline level of carbapenem consumption: reveal-
ing that the institutions that consume carbapenems at a higher baseline rate also
tended to consume them at an increasing rate over time. The implication here is that,
in the absence of external interventions, hospitals are more likely to continue to regress
toward their own mean consumption rates rather than toward a population mean rate.
We chose not to arbitrarily convert DDDs to DOTs in order to allow the “real world”
differences between these centers to become visible. Future studies are needed to
explore this autoregressive tendency and to determine if hospital-specific and nation-
wide benchmarking can be leveraged to improve carbapenem use. In the interim, our
approach can provide to institutions without access to robust benchmarking tools
(such as the NHSN antimicrobial use module, which gives participating facilities access
Rhodes et al. Antimicrobial Agents and Chemotherapy
July 2019 Volume 63 Issue 7 e00327-19 aac.asm.org 10
to SAAR data [28]) an initial framework to (i) make preliminary assessments regarding
their own carbapenem use and (i) determine if interventions targeting carbapenems
are warranted.
Limitations to our analysis should be considered. First, our study was retrospective
and unmeasured confounders are possible. Second, DDD or DOT reporting status may
have been directly linked to the observed trends in consumption rates. Centers that
have the ability to quantitate DOTs may have more-advanced clinical decision support
systems and stewardship programs in place. However, we adjusted for DDD or DOT
reporting status along with several other facility-level demographics in our analysis.
Third, DDDs and DOTs can exhibit imperfect correlations for a variety of antimicrobial
agents (24); however, as measurements, DDDs and DOTs are highly related, and no
measure is completely free from bias (22). We included an interaction term to estimate
the impact of either DDD reporting status or DOT reporting status over time in our
mixed-effects model. Thus, our findings can be readily translated to centers reporting
DDDs or DOTs. Third, the stewardship interventions used to control carbapenem use
were self-reported and may have been inconsistently applied over the study period.
However, variability in the quality and consistency of stewardship interventions was
likely a reality for many centers prior to publication of the Joint Commission’s Antimi-
crobial Stewardship Standard (29). Fourth, our study captured data from only 20
hospitals, a relatively small number considering the total number of hospitals in North
America. However, our sample may be instructive to others seeking to evaluate their
own consumption rates. Fifth, longitudinal bacterial susceptibility data were not eval-
uated as part of this study. Therefore, we are unable to discern the degree to which any
of the model covariates could be surrogates for resistance. Future prospective studies
evaluating both resistance and consumption across centers are needed.
In summary, we identified trends in and predictors of carbapenem consumption
across 20 North American hospitals. Increasing rates of carbapenem consumption in
DDD/1,000 PD were observed over the study period and were independently predicted
by increasing noncarbapenem beta-lactam consumption, hospital and ICU bed size,
and aspects of antibiotic stewardship interventions. Additional studies are needed to
define the impact of uniformly applied stewardship interventions on these metrics and
their ultimate effects on carbapenem resistance across a wider range of diverse health
care institutions.
MATERIALS AND METHODS
A multicenter, retrospective, cross-sectional survey of antimicrobial usage was conducted among
participating hospitals within the Making a Difference in Infectious Diseases (MAD-ID) Research Network
(http://mad-id.org/the-mad-id-research-network/). This network is composed of 181 institutions, 31% of
which are university-affiliated institutions and 52% of which are not-for-profit, nonuniversity hospitals
(30–32). Nearly all (94%) of the network institutions treat adult populations, while 47% care for pediatric
populations and 25% serve the long-term-care population (30–32). This study was approved by the
institutional review board (IRB) at each participating institution. The IRB of Wayne State University
(Detroit, MI) served as the coordinating IRB of record and assisted with all data use agreements (DUA).
Data elements and definitions. Data elements were collected at participating hospitals for the
study period of January 2011 through December 2013. Each center reported antimicrobial use for a
variety of beta-lactam antibiotics in defined daily doses (DDDs) or days of therapy (DOTs) in addition to
hospital or health system demographic information. Defined daily doses were defined according to the
World Health Organization anatomical therapeutic chemical (ATC) standard as grams of drug at a given
facility summated over each quarter (33). Days of therapy data were defined as the tally of all
administrations or orders for a given facility summated over each quarter (22). For this analysis, orders
and administrations were combined for DOTs. All data elements were recorded by volunteer survey
respondents at each study site. Antimicrobial consumption data were collected as quarterly repeated
measures from pharmacy purchasing records (for DDDs) or from the electronic medical record (for DOTs).
Hospital-specific demographics were self-reported by each participating site.
Demographics and stewardship program characteristics. Self-reported hospital demographic
data included primary financial designation (i.e., for profit or not for profit), academic or government
affiliation, patient populations served (e.g., adult, pediatric, neonatal, or long-term care), number of
licensed general ward beds, number of licensed intensive care unit (ICU) beds, the self-reported
antimicrobial stewardship strategies employed (e.g., use of restrictive order forms, circulation of antibi-
ograms), classification of the antimicrobial stewardship strategies employed (e.g., formulary restriction of
carbapenems, prospective audit and feedback of carbapenem use, computer-assisted clinical decision
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support, institutional guidelines, order forms, etc.), and level of restrictions placed on carbapenem use
(e.g., on formulary, not restricted, on restricted formulary, or nonformulary).
Consumption of antimicrobial agents. Participating hospitals reported their rates of consumption
of the following beta-lactams: cefepime, doripenem, ertapenem, imipenem-cilastatin, meropenem, and
piperacillin-tazobactam. The consumption metrics that were reported (e.g., DDDs and DOTs) are com-
monly used to describe antimicrobial utilization at the hospital level and are standardized to patient days
(PD) of hospitalization (e.g., metric/1,000 PD) to adjust for differences in hospital occupancy, which
contribute to each center’s at-risk denominator (34). Patient days were defined as the tally of patients
admitted to each participating facility between census-taking times summated over each quarter, which
is distinct from the more modern NHSN days present (34). Carbapenem consumption rates were
considered to represent a composite of all rates of consumption of any of the following agents:
ertapenem, doripenem, imipenem-cilastatin, and meropenem. Ertapenem was considered together with
the group 2 carbapenems, as it is often used as a step-down agent. Two commonly utilized broad-
spectrum agents, piperacillin-tazobactam and cefepime, were classified as noncarbapenem beta-lactams.
Statistical analysis. (i) Univariate analyses. Demographic predictors of increasing consumption in
DDDs and DOTs were analyzed separately at the univariate level. Descriptive statistics were calculated for
hospital demographic variables. Categorical variables were analyzed using chi-square testing or the
Fisher’s exact test, as appropriate. Differences in carbapenem and noncarbapenem beta-lactam con-
sumption rates were summarized according to hospital demographic characteristics as a ratio of the
median noncarbapenem (NC) consumption rates to the carbapenem (C) consumption rates (i.e., NC/C
ratio). Variability in consumption measures over the study period was quantified as percent coefficient
of variation (i.e., SD/mean  100). Missing data were left as missing in all analyses.
(ii) Multivariate analyses. Multivariate models were fitted to the observed consumption data with
time (in quarters) forced into all regression models, as this was used to determine the presence of
temporal linear trends in consumption rates. Repeated time-dependent consumption rates (i.e., Y  DDD
or DOT/1,000 PD) were modeled using a linear mixed-effects approach. In this approach, consumption
data from all instituions were modeled using fixed-effects (e.g., global intercept and slope estimates
across all hospitals) and random-effects (e.g., random intercept and slope estimates for each hospital)
parameter estimation, as previously described (35). To account for nonindependence of observations
across centers, the following variance-covariance structures were evaluated: (i) single variance with no
covariance (identity), (ii) equal variances with no covariance (independent), (iii) equal variances with
compound symmetrical covariance (exchangable), and (iv) direct covariance estimation (unstructured). A
random slope and intercept mixed-effects variance-covariance matrix, for example, would estimate each
of the parameters shown in Table 5. Noncarbapenem consumption and hospital demographics were
iteratively entered into the base model using a forward-stepwise method for covariate evaluation. To
evaluate inherent differences that might exist between DDD-reporting and DOT-reporting centers over
time, a time-by-metric interaction was evaluated a priori in all models. Stepwise improvements in
multivariate model fitness were evaluated using minimization of Akaike’s information criterion (AIC).
The final covariate-adjusted multivariate linear mixed-effects models were selected by comparing the
final competing models for each metric using likelihood ratio testing. Competing models were assessed
by taking the difference in 2 log-likelihood function values between a model with n  1 predictors
and a model with n predictors (i.e., the same model with one fewer predictor). Goodness of fit for the
final models was evaluated by analysis of regressions of observed and fitted consumption values, mean
weighted prediction error (bias) values, and bias-adjusted mean weighted squared prediction error
(imprecision) values (weighted according to the standard error of the prediction) and by visual inspection
of the homoscedasticity of standardized residuals. Intercooled Stata, version 14.2 (Statacorp, College
Station, TX), was utilized for all model fitting procedures and diagnostics.
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